Bridging the Hot Economics of Monoclonals and Genomics
Abgenix's recent deals with Human Genome Sciences and CuraGen bridge two of the hottest biotechnology markets--monoclonal antibodies and genomics. The deals are structured slightly differently, but both accomplish the same thing: the use of each other's technological asset to create proprietary programs.
You may also be interested in...
Since December 2001, only two privately held antibody firms have raised more than $15 million in a round of financing. Moreover, the older public companies founded on the promise of disruptive antibody development technologies, principally Abgenix and Medarex with fully human antibodies, and Human Genome Sciences with its antibody-driven genomics discovery science, have yet to validate those platforms through successful clinical product development. Even antibody humanization specialist Protein Design Labs, which has marketed antibody products from which it's getting royalties, is still selling for not much more than its cash value. Yet despite a fall-off in investments in this core area of biotech drug development, VCs still say antibodies will provide a range of successful new therapies.
Yuyao YiJia Daily Chemical told FDA placed all drugs it manufactures on import alert in September because its methods and controls for manufacturing OTC sanitizers and other products do not appear to conform to current drug GMPs.
One of the first US telemed bills out of the gate in 2021 calls for permanently ending limits on CMS telehealth payments.